Invivyd, Inc. (IVVD): Nasdaq/NYSE listing notice — Invivyd receives Nasdaq bid price deficiency notice; compliance period ends Oct 20, 2025

Invivyd, Inc.

Received Nasdaq deficiency letter on April 21, 2025 for bid price closing below $1.00 for 30 consecutive business days.
Initial compliance period ends October 20, 2025; needs to close at or above $1.00 for at least ten consecutive business days.
If not compliant by Oct 20, may transfer to Nasdaq Capital Market for a second 180-day period to regain compliance.
No immediate effect on listing; stock continues trading on Nasdaq Global Market under IVVD.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Invivyd, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 21, 2025, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the listi

View on SEC.gov

Browse all listing & compliance notices →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-058705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.